Evidence map›Paper›PMID 39513410›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Noninvasive Immunotyping and Immunotherapy Monitoring of Lung Cancers via Nuclear Imaging of LAG-3 and PD-L1.

Lishu Zhao, Jianxian Ge, Ruru Zhang, Hao Wang, Xinyue Liu, Kandi Xu, Yujin Liu, Wencheng Zhao, Wengang Zhang, Li Ye and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Imaging the fate of CAR-T cellsFrontiers in immunology · 2026
    Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Lishu ZhaoDepartment of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, School of Medicine, Tongji University, No 507 Zhengmin Road, Shanghai, 200433, China.ORCID 0000-0003-4728-9107
Jianxian GeCenter for Molecular Imaging and Nuclear Medicine, State Key Laboratory of Radiation Medicine and Protection, School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou, 215123, China.
Ruru ZhangCenter for Molecular Imaging and Nuclear Medicine, State Key Laboratory of Radiation Medicine and Protection, School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou, 215123, China.
Hao WangDepartment of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, School of Medicine, Tongji University, No 507 Zhengmin Road, Shanghai, 200433, China.
Xinyue LiuDepartment of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, School of Medicine, Tongji University, No 507 Zhengmin Road, Shanghai, 200433, China.
Kandi XuDepartment of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, School of Medicine, Tongji University, No 507 Zhengmin Road, Shanghai, 200433, China.
Yujin LiuDepartment of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, School of Medicine, Tongji University, No 507 Zhengmin Road, Shanghai, 200433, China.
Wencheng ZhaoDepartment of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, School of Medicine, Tongji University, No 507 Zhengmin Road, Shanghai, 200433, China.
Wengang ZhangDepartment of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, School of Medicine, Tongji University, No 507 Zhengmin Road, Shanghai, 200433, China.
Li YeDepartment of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, School of Medicine, Tongji University, No 507 Zhengmin Road, Shanghai, 200433, China.
Zhimin ChenDepartment of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, School of Medicine, Tongji University, No 507 Zhengmin Road, Shanghai, 200433, China.
Jianfeng ZengCenter for Molecular Imaging and Nuclear Medicine, State Key Laboratory of Radiation Medicine and Protection, School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou, 215123, China.
Yayi HeDepartment of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, School of Medicine, Tongji University, No 507 Zhengmin Road, Shanghai, 200433, China.ORCID 0000-0002-2878-8595
Mingyuan GaoCenter for Molecular Imaging and Nuclear Medicine, State Key Laboratory of Radiation Medicine and Protection, School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou, 215123, China.

Funding

2021 Science and Technology Think Tank Youth Talent Plan of China Association for Science and TechnologyClinical Research Project of Shanghai Pulmonary Hospital FKLY20010"Dream Tutor" Outstanding Young Talents Program fkyq1901Fundamental Research Funds for the Central UniversitiesNational Key Research and Development Program of China 2021YFF1200900National Key Research and Development Program of China 2021YFF1201200National Key Research and Development Program of China 2022YFF0705300National Natural Science Foundation of China 52272281Shanghai Municipal Health Commission Health Industry Clinical Research ProjectShanghai Municipal Science and Technology Major Project 2021SHZDZX0100Shanghai Shuguang ScholarYoung Talents in Shanghai 2019 QNBJ
6 · The paper itself

Abstract

Immunotherapy has significantly improved cancer patient survival, while its efficacy remains limited due to the reliance on a single marker like PD-L1 as well as its spatiotemporal heterogeneity. To address this issue, combining lymphocyte activation gene-3 (LAG-3) with PD-L1 is proposed for identifying immunotypes and monitoring immunotherapy through nuclear imaging. In short,

Indexed as

Antigens, CDB7-H1 AntigenImmunotherapyLung NeoplasmsLymphocyte Activation Gene 3 ProteinAnimalsCell Line, TumorDisease Models, AnimalHumansMiceAntigens, CDB7-H1 AntigenCD274 protein, humanLag3 protein, humanLymphocyte Activation Gene 3 ProteinimmunotherapyimmunotypeLAG‐3lung cancernuclear imagingPD‐L1SPECT

Identifiers

PMID39513410
PMCPMC11714153

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.